Dear Client,
As part of our ongoing commitment to ensuring the security of your online trading experience, we would like to inform you of our protocol for addressing any suspicious activities observed on your trading account
Should you notice any irregularities or suspect unauthorized access to your account, we kindly request that you take immediate action by following the steps outlined below:
Send an Email Please send an email to stoptrade@acml.in from your registered email ID. In the email, briefly outline the suspicious activity you have observed.
Phone Call Alternatively, you can call us at 07965081981 Ext: 4 from your registered mobile number. This will enable us to address your concerns promptly.
When contacting us, please ensure you provide the following details:
By providing this information, you enable us to swiftly investigate and take appropriate measures to safeguard your account.
Your security and peace of mind are of utmost importance to us, and we appreciate your cooperation in maintaining the integrity of your trading account.
Revenue from operations margianlly shed 0.38% year on year (YoY) to Rs 60.04 crore in the quarter ended 31 March 2026.
Profit before tax (PBT) stood at Rs 18.44 crore in Q4 FY26, down 31.50% from Rs 26.92 crore recorded in the same quarter last year.
Total expenses jumped 20.42% YoY to Rs 43.74 crore in Q4 FY26. The cost of materials consumed stood at Rs 4.04 crore (up 110.41% YoY), while employee benefit expenses rose 80.61% YoY to Rs 11.74 crore during the period under review.
The company recommended a dividend of Rs 2.40 per equity share of face value Rs 2 each (120%) for FY26.
Alembic is dealing in Active Pharmaceutical Ingredient (API) Business and Real Estate Business.
Powered by Capital Market - Live News